Valuation: Mymetics Corporation

Market Cap 4L 4L 4L 3L 6L 4.2Cr 6L 41.55L 16.2L 2.11Cr 16.48L 16.12L 6.98Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.18Cr 5.78Cr 5.29Cr 9.93Cr 690.06Cr 10Cr 68Cr 27Cr 346.65Cr 27Cr 26Cr 1.15TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 0.0003
0
1 year 0
Extreme 0.0003
0
3 years 0
Extreme 0.0003
20
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-100.00% 45
-3.00%+0.33%+77.39%+109.41% 7.4TCr
+1.90%+23.53%+56.60%+97.76% 6.47TCr
+0.66%+1.99%-4.83%+473.64% 2.73TCr
+4.14%+23.92%+4.14%-1.85% 2.79TCr
+2.74%+11.55%+66.56%+27.34% 2.6TCr
+0.47%+6.12%+36.66%-13.79% 2TCr
+1.82%-3.11%+245.72%+423.83% 1.78TCr
+0.94%+2.38%+24.83%+552.12% 1.62TCr
+0.75%+5.86%+40.13%+153.84% 1.33TCr
Average +1.08%+5.54%+54.72%+172.23% 2.87TCr
Weighted average by Cap. +0.63%+6.66%+59.72%+161.29%

Financials

2021 2022
Net sales 4L 4L 3L 3L 6L 4.11Cr 6L 40.72L 15.88L 2.07Cr 16.15L 15.79L 6.84Cr 10.28L 9L 8L 8L 14.15L 9.84Cr 14.34L 97.35L 37.96L 4.94Cr 38.6L 37.76L 16Cr
Net income -47.3L -40.52L -37.91L -34.7L -65.13L -45Cr -65.99L -4.48Cr -1.75Cr -23Cr -1.78Cr -1.74Cr -75Cr -48.05L -41.16L -38.51L -35.25L -66.16L -46Cr -67.03L -4.55Cr -1.77Cr -23Cr -1.8Cr -1.76Cr -76Cr
Net Debt 6.71Cr 5.75Cr 5.38Cr 4.92Cr 9.24Cr 642.01Cr 9.36Cr 64Cr 25Cr 322.51Cr 25Cr 25Cr 1.07TCr 7.17Cr 6.14Cr 5.75Cr 5.26Cr 9.87Cr 685.87Cr 10Cr 68Cr 26Cr 344.54Cr 27Cr 26Cr 1.14TCr
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock